Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs

NYSE:CVS

CVS Health Corp (CVS)

93.06
+0.14 (0.15%)
as of Aug 28, 2026, 8:00:00 pm Market Open.
411 watching
0
Investor Insights
star iconAug 28, 2026, 12:00 am

This summary was created by AI, based on 9 opinions in the last 12 months.

CVS Health Corp has garnered mixed reviews from experts, reflecting a complex outlook for the company. While recent earnings exceeded expectations and led to a significant share price increase, analysts remain cautious due to underlying challenges in its Caremark business and uncertainties surrounding visibility in earnings. The comparison with higher-quality growth stocks suggests that CVS may have more execution risk, even as its valuation appears cheaper relative to competitors. The company's shift towards a managed care model and the impact of its drugstore segment raises questions about its long-term performance. Overall, CVS could be a compelling option within its sector, especially when considering the potential for recovery and improvements in management strategy.

consensus icon
Consensus
Cautious
valuation icon
Valuation
Undervalued
review icon
Similar
UNH
BUY
They report Wednesday. He expects a very good quarter, partially driven by their Covid testing business. The stock could rise to $110-120.
PAST TOP PICK
(A Top Pick Jan 22/21, Up 46%) Trades at 13x earnings. Still a long way to go. He's very big on pharmacies, as they're delivering more and more services since it's cheaper than via hospitals.
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Nov 26/20, Up 55.5%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with CVS is progressing well. We now recommend trailing up the stop (from $82) to $95. If triggered, this would all but guarantee a net investment gain of 30%, when combined with our previous recommendation to cover half.
PAST TOP PICK
(A Top Pick Jan 19/21, Up 42%) Debt is manageable. Free cashflow of about 13B. Well capitalized. Insurance, pharmacy with HealthHub, pharmacy benefit manager. Not expensive at 13x earnings.
BUY
Has done well, raising estimates for 2022. Redefined itself, and the market's realizing it's more than just a drugstore. Centred around health wellness. Trades at 12x earnings. Good cashflow, decent dividend.
HOLD
The PE is still attractive. CVS is adding more health services in their drug stores. Covid vaccinations encourage consumers to buy more items in their stores when they visit. Still a hold and you'll get a decent return. Still some upside here.
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Nov 26/20, Up 37.69%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with CVS is progressing well. We recommend trailing up the stop (from $70) to $82. If triggered this would result in a net investment gain over 21%, when combined by our previous recommendation to cover half.
COMMENT
They report Wednesday. They've been a roll because of the Covid vaccine and superior execution compared to Walgreens. But can they continue their streak as the pandemic winds down? They do have a huge health insurance business.
PAST TOP PICK
(A Top Pick Feb 26/20, Up 39%) He still likes it. It has a unique business model: a pharmacy, pharmacy benefit management (PBM) and health insurer. Pays a good dividend, diversified and trades around 10x earnings. Free-cash flow yield is almost 9%. It's a durable business.
BUY
It's cheap, and trades well below the market multiple. Booster shots will be a big benefit to CVS.
BUY
Vertically integrated, growing dynamically. CVS has health insurance with Aetna, pharmacy benefit manager with CareMark, and HealthHub offering in-store diagnostics. Better choice than WBA.
PAST TOP PICK
(A Top Pick Aug 21/20, Up 34%) Absolutely he'll stick with it. Trades at a fine PE. It's not just pharmacies but health insurance to add up to a vertical health business.
HOLD
WBA has operations in the US and UK. Stays in drug retail and expands geographically. Doesn't grow quickly, but it's not an income stock either. Growth profile not attractive. She owns CVS instead, with its vertically integrated strategy.
PAST TOP PICK

(A Top Pick Jun 29/20, Up 32%) They became big after buying Aetna. They're broadening offering within stores to offer services like nurse practitioners. They think beyond just being a drug store. They're well-positioned in their industry. Take a long-term view, but you can buy this at current prices.

Showing 151 to 165 of 465 entries